-
-
Bio-tech & New Drugs Innotech Expo R&D of the first-in-class anti-diabetic drug, PS1
This invention is to apply PS1 to treatreverse T2D. The invention can be developed into small-molecule drugs. Those are first-in-class drugs for T2D because its novel anti-diabetic mode of action.
-
-
-
Bio-tech & New Drugs Innotech Expo Multivalent adenoviral vector-based vaccine against hand-food-mouth disease
We developed a recombinant adenovirus Ad-HFMD vaccine which can express virus-like particles (VLPs) of EV71 capsid proteins. Mouse studies showed that Ad-HFMD can induce the protective antibodycellular immunity against EV71CVA16 in hSCARB2 transgenic (hSCARB2-Tg) mouse challenge model.
-
-
-
Bio-tech & New Drugs Innotech Expo Influenza virus-like particle vaccine production using baculovirus expression system
Vaccination is the most effective way to prevent influenza viruses infection. The egg-based production method has many drawbacks, we established baculovirus-based VLPs expression platform for H7N9 VLPs production, purify the VLPs satisfied with FDA regulation,improved its immunogenicity to the same level compared with H7N9 whole virus vaccine.
-
-
-
Bio-tech & New Drugs Innotech Expo Ligands selective to alpha 6 subunit-containing GABAA receptorstheir methods of use
An international collaboration led by Prof. Lih-Chu Chiou, College of Medicine, National Taiwan University, has identified a novel promising drug candidate, the α6-containing GABAA receptor-selective positive allosteric modulator, for the treatment of migraine, trigeminal painneuropsychiatric disorders (schizophreniaTourette syndrome).
-
-
-
Bio-tech & New Drugs Innotech Expo Novel nano-hydrogel technology on medicine, biomaterial, foodcosmetics
1. A novel three-dimensional skin equivalent 2. A supercritical extraction system preserves bioactivity: no toxicity, environmental friendly, high efficiency, refine efficient biological elements 3. Advantages of hydrogel: large area 30 s quick-drying coolpain-killing transparentdifficult to observe moisturization tensioncontraction biodegradation easy to clean / makeup
-
-
-
Bio-tech & New Drugs FutureTech Peripheral Arterial Disease Screening System
In Taiwan, there are almost 96 million people look for medical treatment due to diabetes. The project successfully used the infrared light measurement system to observe the differences between the bilateral feet,collocating with the Chaos Synchronization to measure the differences between different signals, to decrease the probability of the attendance as the ultimate objective .
-
-
-
Bio-tech & New Drugs FutureTech Glycan-maskingglycan-unmasking hemagglutinin antigens for universal influenza vaccine development
The invention provides a glycan-masking and/or glycan-unmasking hemagglutinin, wherein the glycosylation site(s) is added on globular headremoved on stem. The glycan-masking and/or glycan-unmasking hemagglutinin may induce neutralizing antibody against influenza virus,cross-reactive protection against different virus. The invention also provides a method for manufacturing these antigens.
-
-
-
Bio-tech & New Drugs FutureTech Modular Polymeric Nanoshells for Precision AntiviralAnticancer Vaccination
Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.
-
-
-
Bio-tech & New Drugs FutureTech Finding cures – New platformtechniques for the developmenttesting of new drugs for ataxia
Our inter-institutional research team developed RS-D7, a novel NMDAR modulator/DAO inhibitor as a drug candidate for the treatment of ataxia/MSA. Based upon the core symptoms, we designedapplied preclinical mouse behavioral phenotyping techniquesclinical motor assessments to demonstrate the effectiveness of RS-D7our functional assays. RS-D7 offers multi-symptomatic relief.
-
-
-
Bio-tech & New Drugs FutureTech Bi-specific antibodiesuses thereof
We developed a humanized bifunctional antibody (mPEG×tumor marker),the anti-PEG end can be non-covalently modified to bind any PEGylated nano-druga contrast agent by one-step "formulation". The non-covalent binding solved the problems of chemical modification such as the masking of the antibody binding site, heterogeneity, drug instability. The other end of the bifunctional antibody can specifical
-
-
-
Bio-tech & New Drugs FutureTech A genomic marker guided roadmap to treat hepatocellular carcinoma
This is a method for identifying single nucleotide polymorphisms (GALNT14 genotypes) of a target nucleic acid for predicting whether a patient suffering from HCC will respond to combination chemotherapy. Accordingly, physicians can decide whether the HCC patients should receive chemotherapyTACE. This method could also predict prognosis in multiple gastrointestinal cancers.
-
-
-
Bio-tech & New Drugs FutureTech An Anti-Obesity Nanotechnology to Modulate Oil Absorption In Vivo
This technology is mainly solved the side effects of anti-obesity drug, including soft stoolsoily stools,regulate oil absorptionmetabolism as an additive in food. During the experiment, the curing phenomenon of MSNs/oiloily stool reduction in animal were observed. In conclusion, MSNs can effectively reduce the side effects of Orlistatelevating life quality.
-
-
-
Bio-tech & New Drugs FutureTech Composition for treating lung fibrosisemphysematherapeutic method using the same
This is a regenerative biomedical technology, which aims to address the human chronic lung diseases that currently has no pharmaceutical approach for efficient controltherapy, such as COPDlung fibrosis. The principle is to induce the in vivo reprogramming of endogenous alveolar epithelial cells through activation of stemness factor BMI1, which potentiates the repair of injured tissues.
-
-
-
Bio-tech & New Drugs FutureTech A therapeutic gel for diabetic wounds
Our results have demonstrated that our tissue gel can effectively promote angiogenesiswound healing in diabetic wounds. Our product prototype will be a powerful therapeutic product to treat diabetic foot ulcersgo further to rescue diabetic patients from amputation.
-
-
-
Bio-tech & New Drugs FutureTech RSV VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLES AS ADJUVANT
In this project, we have reorganized several highly immunogenic sitesstructurally essential regions to maintain it in a pre-fusion stateuse it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.
-
-
-
Bio-tech & New Drugs FutureTech Develop of novel anti-diabetic agents via targeting endogenous lipid mediators
PPARγ is the master regulator of glucose metabolism.15-keto-PGE2 is an endogenous PPARγ ligand whitch is degraded by ZADH1. We found that increasing 15-keto-PGE2 promotes glucose uptake. We identified several ZADH1 inhibitors which could increase 15-keto-PGE2 promote glucose uptake via activating PPARγ. Our results showed that inhibition of ZADH1 is a novel approach to treat type 2 diabes mell
-
-
-
Bio-tech & New Drugs FutureTech High sensitivity hepatitis B virus large surface protein chemiluminescence quantitative ELISA kit
A high-sensitivity quantitative ELISA detection system for the large HBV surface (LHBS) protein was developed. It includes monoclonal antibodies for LHBSchemiluminescent sandwich ELISA method. Clinical tests of the ELISA prodcuts have been performed in CHB cases. The LHBS detection methodsproducts have been filed for US provisional patentwill be submitted for the IVD approval.
-
-
-
Bio-tech & New Drugs FutureTech Mobile Application for Anti-Doping & Gastroenteritis Defender
1. ‘Mobile Application for Anti-Doping’ containing more than 40,000 pharmaceuticals which allows athletes to check whether the pharmaceuticals are prohibited in-out-of-competition simply via typing in the product names. 2. ‘Gastroenteritis Defender’ utilizes nanotechnology to enhance andrographolide oral bioavailabilitycould effectively prevent gastrointestinal inflammatory disorders.
-
- 1
